e-Drug3D

2038

MARALIXIBAT

INN
MARALIXIBAT

cas 716313-53-0

CLASS

METABOLISM
TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS)
ILEAL BILE ACID TRANSPORTER (IBAT) INHIBITOR

ROUTE (list)

ORAL

ATC code

A05AX04

PK parameters

Tmax 0.75 HOUR
PPB 91 PERCENT
t1/2 1.6 HOUR

Target

TARGET IBAT TRANSPORTER

DrugCentral

Ileal sodium bile acid cotransporter UNIPROT Q12908

Download SDF file

4-Aza-1-azoniabicyclo[2.2.2]octane, 1-[[4-[[4-[(4R,5R)-3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]- (9CI, ACI)

Formula:
C40H56N3O4S

Calculated chemical properties:

MW 674.95
NB_atoms 48
XLogP 6.62
PSA 62.55
NB_HD 1
NB_HA 6
fsp3 0.55
Lipinski(0=no;1=yes) 0

FDA
NDA 214662 (label) INN (MARALIXIBAT CHLORIDE) LIVMARLI (MIRUM) APPROVAL= AP YEAR= 2021 NEWMOLECULARENTITY
NDA 219485 (label) INN (MARALIXIBAT CHLORIDE) LIVMARLI (MIRUM) APPROVAL= AP YEAR= 2025